Daniel Couriel, MD, MS

Daniel Couriel, MD, MS

Daniel R. Couriel, MD, MS

Professor of Internal Medicine

Director, Huntsman Cancer Institute (HCI) Blood and Marrow Transplant Program

University of Utah School of Medicine

Salt Lake City, UT

Related Videos

From a practical implementation perspective, what kind of ports are available for ECP and what is the recommended schedule for deploying ECP in both acute and chronic GVHD? On what basis was this schedule determined? Video

From a practical implementation perspective, what kind of ports are available for ECP and what is the recommended schedule for deploying ECP in both acute and chronic GVHD? On what basis was this schedule determined?

What are the most important randomized studies that support ECP and what do we still need to know about ECP as a foundational, second-line treatment strategy for GVHD? Video

What are the most important randomized studies that support ECP and what do we still need to know about ECP as a foundational, second-line treatment strategy for GVHD?

What length of time is typically required to determine whether ECP has been effective for cGVHD, and when might you consider discontinuation of ECP based on a clinical response to ECP? What is the accepted tapering schedule in responders? Video

What length of time is typically required to determine whether ECP has been effective for cGVHD, and when might you consider discontinuation of ECP based on a clinical response to ECP? What is the accepted tapering schedule in responders?

Are there specific variants or clinical signatures of chronic cGVHD that respond better to ECP therapy than others? What other second line therapies, including ibrutinib, have been evaluated and/or FDA-approved? Video

Are there specific variants or clinical signatures of chronic cGVHD that respond better to ECP therapy than others? What other second line therapies, including ibrutinib, have been evaluated and/or FDA-approved?

Although corticosteroids are the standard first therapy for chronic cGVHD (Graft Versus Host Disease), and multiple second-line treatments have been evaluated for patients who are steroid-refractory or steroid-intolerant, what role does ECP play? Video

Although corticosteroids are the standard first therapy for chronic cGVHD (Graft Versus Host Disease), and multiple second-line treatments have been evaluated for patients who are steroid-refractory or steroid-intolerant, what role does ECP play?

Can you characterize the signs, symptoms, and complications of allogeneic cell transplant, in particular acute and chronic GVHD? Can you distinguish between these two forms of GVHD? What were the classifications provided by the NIH consensus? Video

Can you characterize the signs, symptoms, and complications of allogeneic cell transplant, in particular acute and chronic GVHD? Can you distinguish between these two forms of GVHD? What were the classifications provided by the NIH consensus?

Once you have made the decision to deploy ECP as your second-line therapy for steroid-refractory aGVHD or cGVHD, what practical considerations should clinicians be knowledgeable of when considering ECP treatment? Video

Once you have made the decision to deploy ECP as your second-line therapy for steroid-refractory aGVHD or cGVHD, what practical considerations should clinicians be knowledgeable of when considering ECP treatment?

What is the degree of steroid-sparing effect that can be anticipated when using ECP to treat GVHD? And what complications should be considered to be part of an ECP-dominant treatment strategy for GVHD? Video

What is the degree of steroid-sparing effect that can be anticipated when using ECP to treat GVHD? And what complications should be considered to be part of an ECP-dominant treatment strategy for GVHD?

What is the role of ECP in steroid refractory patients with GVHD? And what is the evidence confirming acceptable response rates and safety of ECP in these patient populations? Video

What is the role of ECP in steroid refractory patients with GVHD? And what is the evidence confirming acceptable response rates and safety of ECP in these patient populations?